Selective CD40-TRAF6 inhibitors for the treatment of inflammatory diseases
The co-stimulatory CD40-CD40L dyad is crucial in the development and progression of immune responses and chronic inflammatory diseases, such as atherosclerosis, obesity and multiple sclerosis. However, long-term antibody-mediated inhibition of CD40L or CD40 is not clinically feasible as it results in thromboembolic events and severe immune suppression. More downstream inhibition of the CD40L-CD40 pathway is therefore preferable, especially tumor necrosis factor receptor-associated factors (TRAFs) recruited by CD40. Here we created a set of inhibitors that selectively block CD40-TRAF6 interactions. The rest of the CD40 cascade is left unaffected preventing unwanted immune-suppressive side effects. Therefore, our new inhibitors offer promising candidates as therapeutic agents for the treatment of chronic inflammatory diseases, such as atherosclerosis, obesity and multiple sclerosis.
Further information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Magnetic tornado is stirring up the haze at Jupiter’s poles
Unusual magnetically driven vortices may be generating Earth-size concentrations of hydrocarbon haze. While Jupiter’s Great Red Spot has been a constant feature of the planet for centuries, University of California,…
Cause of common cancer immunotherapy side effect s
New insights into how checkpoint inhibitors affect the immune system could improve cancer treatment. A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation…
New tool makes quick health, environmental monitoring possible
University of Wisconsin–Madison biochemists have developed a new, efficient method that may give first responders, environmental monitoring groups, or even you, the ability to quickly detect harmful and health-relevant substances…